CTNNB1

protein-coding

catenin beta 1, the group of Beta catenins|Armadillo repeat containing|Wnt enhanceosome complex

Gene summary

The protein encoded by this gene is part of a complex of proteins that constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells. The encoded protein also anchors the actin cytoskeleton and may be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete. Finally, this protein binds to the product of the APC gene, which is mutated in adenomatous polyposis of the colon. Mutations in this gene are a cause of colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2016]

Previous symbols:
  • CTNNB

MANE transcript

NM_001904.4

Inheritance

AD

ClinVar variants

P:265U:371B:186

Top phenotype

Exudative vitreoretinopathy 7; Neurodevelopmental disorder with spastic diplegia and visual defect

gnomAD constraint

pLI —, LoF o/e 0.03

Max pathogenic AF

—

Genomic locus

chr3:41,194,741-41,260,096

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~65.4 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

exudative vitreoretinopathySUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0019516

Submitter: Orphanet

severe intellectual disability-progressive spastic diplegia syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0014035

Submitter: Ambry Genetics

exudative vitreoretinopathy 7MODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0033123

Submitter: Ambry Genetics

severe intellectual disability-progressive spastic diplegia syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0014035

Submitter: Illumina

CTNNB1 was first reported in relation to autosomal dominant CTNNB1-related severe intellectual disability-progressive spastic diplegia syndrom in 2012 (23033978: de Ligt et al. 2012). At least six unique loss of function variants have been reported in humans. Evidence supporting this gene-disease relationship includes case-level and experimental data. Variants in this gene have been reported in at least six probands from three publications (23033978: de Ligt et al. 2012; 25326669: Kuechler et al. 2015; 27915094: Kharbanda et al. 2017). Only de novo variants have been reported in literature. More evidence is available in the literature, but the maximum score for genetic evidence has been reached (12 pts.). The mechanism for disease is haploinsufficiency. This gene-disease association is supported by an animal model and in vitro functional assays (24614104: Tucci et al. 2014). In summary, there is strong evidence to support the relationship between CTNNB1 and CTNNB1-related severe intellectual disability-progressive spastic diplegia syndrome (autosomal dominant). Additional experimental evidence is required to reach a definitive classification.

severe intellectual disability-progressive spastic diplegia syndromeDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0014035

Submitter: G2P

exudative vitreoretinopathy 7STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0033123

Submitter: Labcorp Genetics (formerly Invitae)

severe intellectual disability-progressive spastic diplegia syndromeSUPPORTIVE

Inheritance Pattern: Unknown

Disease ID:MONDO:0014035

Submitter: Orphanet

CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathyDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0100571

Submitter: ClinGen

Heterozygous, usually *de novo*, germline variants in *CTNNB1* have been associated with CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy. The first report of *de novo* truncating variants in *CTNNB1* identified three unrelated patients with a common phenotype of severe intellectual disability with absent or very limited speech, microcephaly and spasticity (de Ligt et al., 2012, PMID: 23033978). Since then, more than 40 patients have been reported in the literature with *de novo* variants in *CTNNB1* (PMIDs: 24668549, 25326669, 27915094, 28514307, 33116939). The spectrum of disease has also expanded to include diagnoses of exudative vitreoretinopathy and other eye abnormalities, either in the presence of the aforementioned neurodevelopmental features or in isolation (PMIDs: 28514307, 28575650, 30640974, 32039639). Per criteria outlined by the ClinGen Lumping & Splitting guidelines and in consultation with the ClinGen Retina Gene Curation Expert Panel (GCEP), we have lumped severe intellectual disability-progressive spastic diplegia syndrome (MONDO:0014035, MIM #615075) and exudative vitreoretinopathy 7 (MONDO:0033123, MIM #617572) for the purposes of this curation. These two disease entities have been curated under the parent term *CTNNB1*-related neurodevelopmental disorder and/or vitreoretinopathy. Both disease entities can exhibit similar defects in retinal vascularization that lead to serous retinal detachment and other ocular features. The proposed disease mechanism is haploinsufficiency, and the observed variant spectrum is similar in both presentations, with the majority of identified variants being nonsense and frameshift variants. There has also been at least one report of a single frameshift variant causing both the syndromic neurodevelopmental presentation and the isolated ocular presentation in unrelated individuals (PMIDs: 28575650, 30929091). Since vitreoretinopathy has been reported in cases without neurodevelopmental features and vice versa (PMIDs: 28575650, 30640974), further investigation of genotype-phenotype correlation and more complete characterization of patients over a longer period of time may be required to better understand the frequency and etiology of isolated phenotypes. *CTNNB1* encodes β-catenin, a component of the cadherin adhesion complex which mediates cell-cell adhesion, and is also part of the Wnt signaling pathway, important for controlling cell growth and differentiation. Experimental evidence *in vitro* and *in vivo* in a mouse model further support the role of *CTNNB1* in disease. In summary, there is definitive evidence supporting the relationship between *CTNNB1* and *CTNNB1*-related neurodevelopmental disorder and/or vitreoretinopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was originally evaluated by the ClinGen Intellectual Disability and Autism GCEP on February 3, 2021. It was reevaluated by the Retina GCEP and Intellectual Disability and Autism GCEP on February 8, 2024 (SOP 11), resulting in the change of the disease name as discussed above. The classification, however, did not change.

exudative vitreoretinopathyDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0019516

Submitter: G2P

severe intellectual disability-progressive spastic diplegia syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0014035

Submitter: Labcorp Genetics (formerly Invitae)

Clinical Genomic Database (CGD)

Exudative vitreoretinopathy 7; Neurodevelopmental disorder with spastic diplegia and visual defectAD

Manifestation: Craniofacial; Neurologic; Ophthalmologic

Intervention: General

Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing

Refs: 23033978; 24614104; 24668549; 25326669; 27915094; 28514307; 28575650Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to CTNNB1 variants in ClinVar

47 Conditions Cataloged
not providedTotal: 778
Severe intellectual disability-progressive spastic diplegia syndromeTotal: 123
not specifiedTotal: 87
CTNNB1-related disorderTotal: 66
Inborn genetic diseasesTotal: 61
Exudative vitreoretinopathy 7Total: 21
PilomatrixomaTotal: 20
Hepatocellular carcinomaTotal: 18

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_001904.4. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
1
clinvar
5
clinvar
161
clinvar
6
clinvar
173
missense
10
clinvar
24
clinvar
353
clinvar
19
clinvar
406
nonsense
46
clinvar
12
clinvar
1
clinvar
59
start loss
1
clinvar
1
frameshift
109
clinvar
29
clinvar
1
clinvar
139
splice donor/acceptor (+/-2bp)
16
clinvar
18
clinvar
10
clinvar
44
Total182833711806822

Highest pathogenic variant AF is 0.0000024783023

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 113 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_001904.4RefSeqNP_001895.114MANE Select
ENST00000349496.11EnsemblENSP00000344456.514MANE Select
NM_001098209.2RefSeqNP_001091679.114Standard
NM_001098210.2RefSeqNP_001091680.114Standard

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
ctnnb1Danio rerio

Structure: post-vent region

Quality: curved ventral

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Gastric cancer - Homo sapiens (human)
  • Focal adhesion - Homo sapiens (human)
  • Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human)
  • Adherens junction - Homo sapiens (human)
  • Cushing,s syndrome - Homo sapiens (human)

Biological Process

  • negative regulation of transcription by RNA polymerase II
  • embryonic axis specification
  • cell morphogenesis involved in differentiation
  • branching involved in blood vessel morphogenesis
  • branching involved in ureteric bud morphogenesis

Molecular Function

  • RNA polymerase II transcription factor binding
  • RNA polymerase II activating transcription factor binding
  • chromatin binding
  • DNA-binding transcription factor activity
  • transcription coactivator activity

Cellular Component

  • spindle pole
  • nucleus
  • nucleoplasm
  • transcription factor complex
  • nuclear euchromatin

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000349496
Coding exons
14
Length
65260
Individuals with no LoFs
125682
Homozygous LoFs
0
Heterozygous LoFs
1
Defined
125683
p
0.00000398
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense3.851994210.4730.00002465096
Missense (PolyPhen)2276.4280.28785982
Synonymous0.1391391410.9850.000007131589
Loss of Function5.46136.70.02720.00000226409

Population LoF Frequency

PopulationCAFp-valueStatus
African00.0absent
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian0.0000540.000054rare
Finnish00.0absent
European (Non-Finnish)00.0absent
South Asian00.0absent
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion, as component of an E- cadherin:catenin adhesion complex. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML (PubMed:17524503, PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, PubMed:22647378, PubMed:22699938, PubMed:22155184). Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle (By similarity). {ECO:0000250|UniProtKB:Q02248, ECO:0000269|PubMed:17524503, ECO:0000269|PubMed:18077326, ECO:0000269|PubMed:18086858, ECO:0000269|PubMed:18957423, ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:22155184, ECO:0000269|PubMed:22647378, ECO:0000269|PubMed:22699938}.;
Disease
DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. {ECO:0000269|PubMed:9065402}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Note=Activating mutations in CTNNB1 have oncogenic activity resulting in tumor development. Somatic mutations are found in various tumor types, including colon cancers, ovarian and prostate carcinomas, hepatoblastoma (HB), hepatocellular carcinoma (HCC). HBs are malignant embryonal tumors mainly affecting young children in the first three years of life.; DISEASE: Pilomatrixoma (PTR) [MIM:132600]: Common benign skin tumor. {ECO:0000269|PubMed:10192393, ECO:0000269|PubMed:11703283, ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry is involved in disease pathogenesis.; DISEASE: Medulloblastoma (MDB) [MIM:155255]: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. {ECO:0000269|PubMed:10666372, ECO:0000269|PubMed:12027456}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. {ECO:0000269|PubMed:10391090}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Note=A chromosomal aberration involving CTNNB1 is found in salivary gland pleiomorphic adenomas, the most common benign epithelial tumors of the salivary gland. Translocation t(3;8)(p21;q12) with PLAG1.; DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle- shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. {ECO:0000269|PubMed:11464291}. Note=The gene represented in this entry may be involved in disease pathogenesis.; DISEASE: Mental retardation, autosomal dominant 19 (MRD19) [MIM:615075]: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD19 features include severe intellectual disability with absent or very limited speech, microcephaly, and spasticity which severely impaired the ability to walk. {ECO:0000269|PubMed:23033978, ECO:0000269|PubMed:25326669, ECO:0000269|PubMed:28514307}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Vitreoretinopathy, exudative 7 (EVR7) [MIM:617572]: A form of exudative vitreoretinopathy, a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. {ECO:0000269|PubMed:28575650}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.996

Intolerance Scores

LoFtool
0.208
RVIS EVS
-0.58
RVIS percentile EVS
18.44

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
S
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
1.00

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.